Trial · NCT01503372
FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer
NCT01503372, Phase 2, Completed, Charite University, Berlin, Germany
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer. Trials, record NCT01503372. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01503372
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer
- NCT number
- NCT01503372
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 75 participants, actual
- Lead sponsor
- Charite University, Berlin, Germany
- Conditions
- Advanced Gastric Cancer
- Interventions
- Pazopanib, 5-FU, Oxaliplatin, Leukovorin (FLO)
- First posted
- 2012-01-04
- Last updated
- 2019-02-12
- Other registries' IDs
- eudract:2010-024379-15
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | progression-free survival rate at 6 months | 6 months after study entry | |
| Secondary | progression-free survival rate at 9 and 12 months | 9 and 12 months after study entry | |
| Secondary | median progression-free survival | 48 months | |
| Secondary | response rate | 48 months | |
| Secondary | duration of response | 48 months | |
| Secondary | toxicity | 48 months | number of patients with Adverse Events according to CTC-criteria |
| Secondary | tolerability | 48 months | number of patients having adverse events and require interruptions and dose reductions of chemotherapy |
| Secondary | overall survival | 48 months | |
| Secondary | time to treatment failure | 48 months | |
| Secondary | evaluation of the predictive and prognostic relevance of biomarkers | 48 months | collection of plasma samples at designated time points during treatment and measuring of angiogenic factors correlating with response rate and outcome |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01503372
GET https://conductscience.org/api/trials/v1/NCT01503372/registered